VEGFA and neoplasm: These studies were performed on tumor xenografts and orthotopic tumor models treated with different classes of anti-angiogenic agents, such as the VEGF-directed antibody bevacizumab, the VEGF-receptor directed antibody DC101, the anti-angiogenic peptide anginex or multiple VEGF-RTK-inhibitors [309, 317–321].